Skip to main content
Log in

Cisplatin/Epinephrine Injectable Gel

  • Adis New Drug Profile
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

  • ▲ Cisplatin/epinephrine injectable gel is a preparation for intratumoural injection containing cisplatin 4 mg/ml, epinephrine (adrenaline) 0.1 mg/ml and bovine collagen as a protein carrier matrix. It has been evaluated for the palliative treatment of accessible inoperable metastatic or recurrent solid tumours.

  • ▲ The vasoconstrictor action of epinephrine limits the diffusion of cisplatin into the systemic circulation. Intratumoural injection of cisplatin/epinephrine injectable gel achieves high concentrations of cisplatin in the tumour with very low concentrations in plasma and other tissues.

  • ▲ In double-blind randomised trials, cisplatin/epinephrine injectable gel was more efficacious than placebo in the palliative treatment of recurrent and resistant head and neck squamous cell carcinoma.

  • ▲ Cisplatin/epinephrine injectable gel reduced tumour size and improved local symptoms in patients with metastatic breast cancer, metastatic malignant melanoma, oesophageal carcinoma and hepatic tumours in a number of noncomparative clinical trials.

  • ▲ Adverse events with the use of cisplatin/epinephrine injectable gel are mainly limited to the local site of injection. No systemic adverse events such as nephrotoxicity, neurotoxicity or ototoxicity have been reported with use of this preparation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kanekal S, Sahai A, Yu NY, et al. Rational design and development of a cisplatin/epinephrine injectable gel for intralesional treatment of accessible tumors: from preclinical models to clinical outcome [abstract]. Ann Oncol 1996; 7Suppl. 1: 136

    Google Scholar 

  2. Kitchell BE, Brown DM, Luck EE, et al. Intralesional implant for treatment of primary oral malignant melanoma in dogs. J Am Vet Med Assoc 1994 January 15; 204(2): 229–36

    PubMed  CAS  Google Scholar 

  3. Davidson BS, Izzo F, Cromeens DM, et al. Collagen matrix cisplatin prevents local tumor growth after margin-positive resection. J Surg Res 1995; 58: 618–24

    Article  PubMed  CAS  Google Scholar 

  4. Yu N, Peña R, Patawaran M, et al. Increased local tumor control and improved survival rate in mice with cisplatin by combining intratumoral and systemic routes of administration [abstract no. 3906]. Proceedings of the American Association for Cancer Research 1999 Mar; 40: 592

    CAS  Google Scholar 

  5. Ning S, Yu N, Brown DM, et al. Radiosensitization by intratumoral administration of cisplatin in a sustained-release delivery system. Radiother Oncol 1999; 50: 215–23

    Article  PubMed  CAS  Google Scholar 

  6. Theon AP, Madewell BR, Ryu J, et al. Concurrent irradiation and intratumoral chemotherapy with cisplatin: a pilot study in dogs with spontaneous tumors. Int J Radiat Oncol Biol Phys 1994; 29(5): 1027–34

    Article  PubMed  CAS  Google Scholar 

  7. Korey A, Siddik ZH, Curley SA, et al. Intratumoral cisplatin implant (MPI 5010) for treatment of solid tumors: dose distribution in rabbit VX2 liver tumors [abstract no. 2187]. Proceedings of the American Association for Cancer Research 1993 Mar; 34: 367

    Google Scholar 

  8. Curley SA, Davidson S, Carrasco CH, et al. Intratumoral sustained-release chemotherapy with cisplatin/epinephrine gel in patients with primary or metastatic cancer of the liver [abstract no. 071]. 9th Mediterranean Congress of Chemotherapy: 1994 Jun 12–17; Milan, 65

  9. Mok TSK, Kanekal S, Lin XR, et al. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. Cancer 2001; 91(12): 2369–77

    Article  PubMed  CAS  Google Scholar 

  10. Burris HA 3rd, Vogel CL, Castro D, et al. Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study. Otolaryngol Head Neck Surg 1998 Apr; 118: 496–503

    Article  PubMed  Google Scholar 

  11. Werner JA, Castro D, Sridhar K, et al. Intratumoral cisplatin/epinephrine injectable gel for treatment of head and neck cancer squamous cell carcinoma provides local tumor control and improved quality of life: phase III multicenter studies [abstract no.406PD/poster]. Ann Oncol 2000; 11Suppl. 4: 91

    Google Scholar 

  12. Sridhar K, Werner J, Castro D, et al. Intratumoral cisplatin/epinephrine (CDDP/epi) injectable gel achieves tumor ablation and clinical benefit in patients with advanced head and neck squamous cell carcinoma (HNSCC): multicenter phase III placebo-controlled trials [abstract no. 917]. 37th Annual Meeting of the American Society of Clinical Oncology 2001; 20 (Pt l): 230a

    Google Scholar 

  13. Harbord M, Eysselein V, Viens P, et al. Intratumoral injection of cisplatin/epinephrine gel for palliation of dysphagia in patients with advanced esophageal cancer [abstract no. 206]. Gastrointest Endosc 1999 Apr; 49 (4 Pt 2): AB 104

    Google Scholar 

  14. Monga SPS, Wadleigh R, Sharma A, et al. Intratumoral therapy of cisplatin/epinephrine injectable gel for palliation in patients with obstructive esophageal cancer. Am J Clin Oncol 2000 Aug; 23: 386–92

    Article  PubMed  CAS  Google Scholar 

  15. Fernando I, Eisenberg PD, Roshon S, et al. Intratumoral focused chemotherapy with cisplatin/epinephrine injectable gel for palliative treatment of metastatic breast cancer [abstract no. 1278]. Eur J Cancer 1999 Sep; 35Suppl. 4: S318

    Article  Google Scholar 

  16. Oratz R, Hauschild A, Sebastian G, et al. Intratumoural cisplatin/epinephrine injectable gel provides palliative tumour control for patients with metastatic melanoma [abstract no. 1521]. Eur J Cancer 1999 Sep; 35Suppl. 4: S374

    Article  Google Scholar 

  17. Johnson P, Leung TWT, Vogl TJ, et al. Management of unresectable hepatocellular carcinoma with cisplatin/epinephrine injectable gel administered percutaneously: radiologic and histologic evidence of tumor ablation [abstract no. 639P]. Ann Oncol 2000; 11Suppl. 4: 139–40

    Google Scholar 

  18. Vogl TJ, Engelmann K, Lipton A, et al. Percutaneous cisplatin/epinephrine (CDDP/epi) injectable gel treatment for metastatic colorectal adenocarcinoma limited to the liver [abstract no. 233P/poster]. Ann Oncol 2000; 11Suppl. 4: 53–4

    Google Scholar 

  19. Thuluvath PJ, Geschwind JF, Johnson PJ, et al. Management of hepatoma using cisplatin/epinephrine gel in patients awaiting orthotopic liver transplantation. Transplant Proc 2001; 33: 1359–60

    Article  PubMed  CAS  Google Scholar 

  20. Yu SCH, Leung TWT, Lau WY, et al. Local effect of cisplatin/epinephrine injectable gel on intrahepatic lesions of hepatocellular carcinoma [abstract no. 537]. Eur J Cancer 1999 Sep; 35Suppl. 4: S146

    Article  Google Scholar 

  21. Monga SP, Wadleigh R, Adib H, et al. Endoscopic treatment of gastric cancer with intratumoral cisplatin/epinephrine injectable gel: a case report. Gastrointest Endosc 1998 Oct; 48: 415–7

    Article  PubMed  CAS  Google Scholar 

  22. Kempf W, Burg G, Hill DM, et al. Intralesional cisplatin-epinephrine-collagen gel for the treatment of cutaneous B-cell lymphoma [abstract no. P21]. J Invest Dermatol 1997 Sep; 109(3): 495

    Google Scholar 

  23. Johnson PJ, Yu SCH, Vogl TJ, et al. Percutaneous administration of cisplatin/epinephrine (CDDP/EPI) injectable gel for treatment of intrahepatic hepatocellular carcinoma (HCC) [abstract no. 23]. Cancer Invest 2000; 18 Suppl. 1: 28–9

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Greg L. Plosker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malhotra, H., Plosker, G.L. Cisplatin/Epinephrine Injectable Gel. Drugs & Aging 18, 787–793 (2001). https://doi.org/10.2165/00002512-200118100-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200118100-00007

Keywords

Navigation